ALOX5 and its coded protein, 5-LO, has long been recognized as a predictive marker for patients with GBM, which was consistent with the prediction model [29,30], while STEAP3 was reported as a negative predictor of OS for patients with GBM [31]. This evidence concerns the gene STEAP3 and glioblastoma.